Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Glibenclamide in Type 2 Diabetes Mellitus - Part A (LEGEND-A)
2015-002837-23Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of glibenclamide in type 2 diabetes mellitus (T2DM), sponsored by University of Oxford. Primary endpoint: Fasting plasma glucagon concentration. Started Apr 2016; status: completed.
02
Drugs
glibenclamide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-002837-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002837-23.